Compare CLPS & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLPS | COCH |
|---|---|---|
| Founded | 2005 | 1995 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Blank Checks |
| Sector | Technology | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.3M | 24.4M |
| IPO Year | 2018 | N/A |
| Metric | CLPS | COCH |
|---|---|---|
| Price | $0.87 | $0.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.50 |
| AVG Volume (30 Days) | 14.5K | ★ 448.5K |
| Earning Date | 10-17-2025 | 11-10-2025 |
| Dividend Yield | ★ 14.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $164,481,414.00 | $208,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $29.53 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 15.17 | N/A |
| 52 Week Low | $0.82 | $0.64 |
| 52 Week High | $1.88 | $2.25 |
| Indicator | CLPS | COCH |
|---|---|---|
| Relative Strength Index (RSI) | 51.10 | 50.34 |
| Support Level | $0.87 | $0.80 |
| Resistance Level | $0.98 | $0.86 |
| Average True Range (ATR) | 0.03 | 0.05 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 38.16 | 59.29 |
CLPS Inc. is an IT consulting and solutions provider serving international clients in the banking, wealth management, e-commerce, and automotive sectors. The company drives digital transformation using AI, cloud computing, and big data, offering IT consulting, customized solutions, virtual banking training, recruitment, professional training, and software services. It operates mainly in two segments: IT services, which generate the majority of its revenue, and academic education services. The company has a presence in Hong Kong, Singapore, Mainland China, India, Malaysia, and Japan, with the majority of its revenue coming from Mainland China.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.